Invention Grant
US09045542B2 Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) 有权
通过Dectin-1或toll样受体2(TLR2)激活人类DCs来控制过敏和哮喘

Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
Abstract:
The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.
Information query
Patent Agency Ranking
0/0